Vanda Pharmaceuticals (VNDA) said Monday that it submitted a new drug application with the US Food and Drug Administration requesting marketing approval for Bysanti to treat acute bipolar I disorder and schizophrenia.
The company started a phase 3 study of the drug as a once-daily add-on treatment for major depressive order in Q4, with results expected in 2026.
Shares of the company were down 2.1% in recent trading.
Price: 4.59, Change: -0.10, Percent Change: -2.13
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。